IMPORTANT SAFETY INFORMATION

Do not take NEXAVAR if you have a specific type of lung cancer (squamous cell) and receive carboplatin and paclitaxel or if you are allergic to sorafenib or any of the other ingredients in NEXAVAR. Before starting NEXAVAR, tell your doctor if you have: allergies, heart problems (including a problem called “congenital long QT syndrome”) or chest pain, bleeding or bruising problems, high blood pressure, any planned surgical procedures, lung cancer or are being treated for lung cancer, kidney problems in addition to kidney cancer, or liver problems in addition to liver cancer. Tell your doctor if you are pregnant or plan to become pregnant and if you are breast-feeding or plan to breast-feed. It is not known if NEXAVAR passes into your breast milk. You and your doctor should decide if you will take NEXAVAR or breast-feed. You should not do both.
continue reading below »

  •  

REACH Co-Pay Assistance

A New Level of Financial Support for Privately-insured NEXAVAR® Patients*

Up to $4,000 per prescription and up to $16,000 per year per patient for privately-insured patients.

If Prior Authorization determination is delayed or denied, patients may be assessed for temporary patient assistance.

  • Only privately-insured patients who were not previously enrolled in the REACH commercial co-pay assistance program are eligible for this program
  • Patients enrolled in Medicare, Medicaid, or any government-funded programs are not eligible for $0 Co-Pay Assistance
  • REACH us by phone: 1.866.639.2827
  • REACH us online: www.REACHPatientSupport.com »
  • REACH enrollment forms may also be downloaded and printed from the REACH enrollment page.
  • REACH counselors work directly with specialty pharmacy providers to help ensure you get the Nexavar therapy you have been prescribed.

*Patients who are enrolled in any type of government insurance or reimbursement programs are not eligible. As a condition precedent of the co-payment support provided under this program, e.g., co-pay refunds, participating patients and pharmacies are obligated to inform insurance companies and third-party payors of any benefits they receive and the value of this program, as required by contract or otherwise. Void where prohibited by law, taxed, or restricted. Patients enrolled in Bayer's Patient Assistance Program are not eligible. Bayer and Onyx may determine eligibility, monitor participation, equitably distribute product and modify or discontinue any aspect of the REACH program at any time, including but not limited to this commercial co-pay assistance program.